Display options
Cite
Akhtar N, Taher A, Rahman R, et al. Serum complements and heart fatty acid binding protein in Bangladeshi patients with acute myocardial infarction. Heart Asia. 2012;4(1):125-8doi: 10.1136/heartasia-2012-010164.
Akhtar, N., Taher, A., Rahman, R., & Chowdhury, A. K. (2012). Serum complements and heart fatty acid binding protein in Bangladeshi patients with acute myocardial infarction. Heart Asia, 4(1), 125-8. https://doi.org/10.1136/heartasia-2012-010164
Akhtar, Nayareen, et al. "Serum complements and heart fatty acid binding protein in Bangladeshi patients with acute myocardial infarction." Heart Asia vol. 4,1 (2012): 125-8. doi: https://doi.org/10.1136/heartasia-2012-010164
Akhtar N, Taher A, Rahman R, Chowdhury AK. Serum complements and heart fatty acid binding protein in Bangladeshi patients with acute myocardial infarction. Heart Asia. 2012 Sep 26;4(1):125-8. doi: 10.1136/heartasia-2012-010164. eCollection 2012. PMID: 27326047; PMCID: PMC4832623.
Copy Download .nbib Format: NLM
Share it on

Heart Asia. 2012 Sep 26;4(1):125-8. doi: 10.1136/heartasia-2012-010164. eCollection 2012.

Serum complements and heart fatty acid binding protein in Bangladeshi patients with acute myocardial infarction.

Heart Asia

Nayareen Akhtar, Abu Taher, Rezwanur Rahman, Ashesh Kumar Chowdhury

Affiliations

  1. Department of Immunology, Bangladesh Institute of Research in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Dhaka, Bangladesh.
  2. Department of Nephrology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

PMID: 27326047 PMCID: PMC4832623 DOI: 10.1136/heartasia-2012-010164

Abstract

The complement system is activated following acute myocardial infarction (AMI). Heart fatty acid binding protein (H-FABP) is a sensitive early biomarker of myocardial necrosis that can be used to confirm or exclude a diagnosis of AMI and to monitor recurrent infarction. This study was designed to detect changes in C3, C4 and H-FABP after AMI. Forty patients with AMI and a control group of 40 apparently healthy people were included. Selections were based on inclusion and exclusion criteria. The baseline characteristics were not significantly different between the groups. Patients' blood samples were collected within 12 h of admission. Significant increases in C3 (AMI group 1.4260+0.04, healthy group 1.26040+0.04; p<0.05), C4 (AMI group 0.29305±0.013, healthy group 0.20860±0.012; p<0.05) and H-FABP (AMI group 12.3±1.69, healthy group 0.16±0.057; p<0.001) were seen in patients with AMI. The correlation between serum C3 and body mass index (BMI, r=0.33; p<0.05), serum C4 and BMI(r=0.313; p<0.05), serum C3 and total cholesterol high density lipoprotein (HDL, r=0.32; p<0.05), serum C4 and HbA1C (r=0.335; p<0.05) and serum C3 and troponin I (r= 0.325p<0.05) was found to be significant. But the correlation between serum C3 and waist:hip ratio (p=0.56), serum C4 and waist:hip ratio (p=0.83), serum C4 and total cholesterol HDL (p=0.993), serum C3 and HbA1C (p=0.440), serum C3 and random blood sugar (p=0.563), serum C4 and random blood sugar (p=0.828) and serum C4 and troponin I (p=0.373) was not significant. The significant complement activation detected in the plasma of patients with AMI indicated that complement plays a part in the pathogenesis of myocardial infarction. A significant increase of H-FABP improves the diagnosis of AMI.

Keywords: Imaging And Diagnostics; Myocardial Ischaemia And Infarction (IHD)

References

  1. Atherosclerosis. 1988 Mar;70(1-2):95-105 - PubMed
  2. Mol Cell Biochem. 1992 Oct 21;116(1-2):155-62 - PubMed
  3. J Immunol Methods. 2003 Aug;279(1-2):91-100 - PubMed
  4. Heart Vessels. 1995;10 (6):304-9 - PubMed
  5. J Exp Med. 1971 Apr 1;133(4):885-900 - PubMed
  6. Nature. 1979 Mar 8;278(5700):176-8 - PubMed
  7. J Immunol. 1973 May;110(5):1376-82 - PubMed
  8. Am J Cardiol. 1977 Oct;40(4):550-5 - PubMed
  9. Eur Heart J. 2000 Jul;21(13):1081-90 - PubMed
  10. Jpn Circ J. 1983 Mar;47(3):289-93 - PubMed
  11. Springer Semin Immunopathol. 1984;7(2-3):193-219 - PubMed
  12. Circ Res. 1988 Mar;62(3):572-84 - PubMed
  13. Eur J Cardiovasc Prev Rehabil. 2007 Jun;14(3):392-7 - PubMed
  14. N Engl J Med. 2001 Apr 12;344(15):1140-4 - PubMed
  15. J Am Coll Cardiol. 1987 Sep;10(3):627-32 - PubMed
  16. Circulation. 1990 Jan;81(1):156-63 - PubMed
  17. J Clin Invest. 1980 Nov;66(5):1050-6 - PubMed
  18. Clin Chim Acta. 2005 Feb;352(1-2):15-35 - PubMed
  19. Circulation. 1995 Nov 15;92 (10 ):2848-54 - PubMed
  20. Science. 1990 Jul 13;249(4965):146-51 - PubMed
  21. APMIS. 2005 Mar;113(3):167-74 - PubMed

Publication Types